ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR
In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed
ORIC's cancer drug showed strong early results fighting lung cancer. Watch how the big trial goes to learn if it really works better.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.